Affinage

IFITM1

Interferon-induced transmembrane protein 1 · UniProt P13164

Length
125 aa
Mass
14.0 kDa
Annotated
2026-06-10
100 papers in source corpus 38 papers cited in narrative 38 extracted findings
Cross-family judge vs UniProt: tie faithfulness: 10/10 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

IFITM1 is an interferon-induced transmembrane protein that restricts entry and replication of diverse viruses while also serving as a signaling and developmental effector in non-viral contexts (PMID:8727077, PMID:16847454, PMID:22996292). As an antiviral restriction factor, IFITM1 blocks vesicular stomatitis virus and acts at post-entry or entry steps against HCV, where it localizes to hepatocyte tight junctions and physically interacts with the HCV co-receptors CD81 and occludin to disrupt viral entry (PMID:8727077, PMID:21976647, PMID:22996292). Its antiviral activity and protein stability depend critically on S-palmitoylation of conserved cysteines, which is countered by the depalmitoylase ABHD16A and indirectly enhanced by ABHD17A through suppression of ABHD16A (PMID:23804635, PMID:40723864, PMID:40434075). IFITM1 intracellular distribution and membrane topology are governed by a C-terminal non-canonical dibasic (KRXX) sorting signal that binds adaptor protein complex AP-3, directing the protein among endosomal compartments and the plasma membrane and thereby tuning which viruses it restricts (PMID:25527505, PMID:25738301). Distinct from restriction, IFITM1 can facilitate cholesterol transport from late endosomes to the Golgi, a function exploited by the non-enveloped Aichi virus to build cholesterol-rich replication sites, where IFITM1 associates with ACBD3, PI4KB, and OSBP (PMID:37252940). In non-viral signaling, IFITM1 functions downstream of STAT1 to mediate IFN-γ antiproliferative effects by inhibiting ERK—partly through interaction with caveolin-1 at caveolae—and by stabilizing p53 (PMID:16847454, PMID:19499152). IFITM1 also supports IFN-γ-driven MHC class I expression and immune surveillance of metastatic cells, acting at the translational level to promote HLA-B synthesis and secreting complement C3 to recruit microglia (PMID:30951861, PMID:36008984, PMID:36799040). In development, IFITM1 mediates repulsion of primordial germ cells via its N-terminal extracellular domain (PMID:16326387). Its transcription is controlled by STAT1/STAT2 binding to a distal IFN-responsive enhancer engaged through long-range chromatin looping (PMID:28511927). Across cancers IFITM1 has context-dependent pro- or anti-tumor roles, frequently signaling through CAV-1 and NF-κB (PMID:27852071, PMID:34022283).

Mechanistic history

Synthesis pass · year-by-year structured walk · 24 steps
  1. 1993 Medium

    Established the first functional activity for the interferon-inducible 9-27 protein, framing IFITM1 as an antiviral effector capable of binding RNA and interfering with viral gene expression.

    Evidence cDNA library screen for RRE-binding proteins, in vitro RNA-binding assay, and HIV-1 expression assay after transfection in human cells

    PMID:7680491

    Open questions at the time
    • RNA binding shown in vitro only, with unclear physiological relevance
    • Did not establish whether antiviral effect was direct or via host signaling
  2. 1996 Medium

    Demonstrated that IFITM1 has intrinsic, virus-selective antiviral activity (active against VSV, inactive against influenza), establishing virus specificity as a defining feature.

    Evidence Constitutive expression of 9-27 cDNA in mouse cells with single-cell virus resistance assay and immunofluorescence localization

    PMID:8727077

    Open questions at the time
    • Mechanistic basis of virus selectivity not defined
    • Subcellular localization only described qualitatively
  3. 1998 Medium

    Linked IFITM1 to epithelial cell-cell junction biology by showing its ortholog is required for dome formation in mammary epithelia, revealing a non-antiviral cellular role.

    Evidence Subtractive cDNA library, antisense suppression, forced overexpression, and in situ hybridization in rat mammary epithelial cells

    PMID:9448288

    Open questions at the time
    • Molecular partners at junctions not identified
    • Used the rat ortholog rather than human IFITM1
  4. 2005 High

    Defined a developmental function in primordial germ cell repulsion and mapped it to the N-terminal extracellular domain, demonstrating domain-specific, non-antiviral signaling.

    Evidence Loss-of-function in mouse embryos plus domain-swap chimera analysis and PGC migration tracking

    PMID:16326387

    Open questions at the time
    • Receptor/ligand mediating repulsion not identified
    • Downstream signaling unknown
  5. 2006 High

    Placed IFITM1 downstream of STAT1 as a required mediator of IFN-γ antiproliferative signaling, connecting it to ERK inhibition and p53 stabilization and to tumor suppression.

    Evidence Overexpression and siRNA knockdown with ERK and p53 reporter/phosphorylation assays and nude mouse tumorigenicity assay

    PMID:16847454

    Open questions at the time
    • Direct molecular target by which IFITM1 inhibits ERK not defined here
    • Mechanism of p53 Thr55 phosphorylation prevention unresolved
  6. 2009 Medium

    Identified caveolin-1 as a physical partner, providing a molecular route by which IFITM1 enhances ERK inhibition without itself being a kinase.

    Evidence Immunofluorescence, co-immunoprecipitation, deletion mutagenesis, ERK phosphorylation assay, and CAV-1 knockdown

    PMID:19499152

    Open questions at the time
    • Single-lab interaction without reciprocal validation in multiple systems
    • How transmembrane-domain binding modulates CAV-1 activity not structurally defined
  7. 2010 Medium

    Showed IFITM1 is induced via CD147/cyclophilin A through ERK, PI3K, and NF-κB and can itself drive proinflammatory output, implicating it in inflammatory signaling.

    Evidence Pathway inhibitors, RT-PCR, Western blot, and antibody cross-linking of IFITM1 in THP-1 macrophages

    PMID:20847954

    Open questions at the time
    • Cross-linking is a surrogate for natural ligation
    • Direct downstream effectors of IFITM1 signaling not mapped
  8. 2011 Medium

    Established IFITM1 as an anti-HCV factor acting post-entry, distinguishing its mechanism from a pure entry block.

    Evidence Bidirectional overexpression and knockdown in IHH and Huh7 cells with HCV replication and pseudotype entry assays

    PMID:21976647

    Open questions at the time
    • Post-entry step not molecularly defined
    • Apparent tension with later entry-block findings unresolved
  9. 2012 High

    Localized IFITM1 to hepatocyte tight junctions and identified CD81 and occludin as binding partners, defining an entry-disruption mechanism against HCV relevant in patient tissue.

    Evidence Reciprocal Co-IP, confocal localization in cells and patient liver biopsies, and functional HCV entry assays

    PMID:22996292

    Open questions at the time
    • Whether IFITM1 blocks entry by occluding co-receptors or altering membrane properties not resolved
    • Reconciliation with the earlier post-entry result not addressed
  10. 2013 High

    Defined the trafficking and topology determinants of IFITM1: a C-terminal dibasic KRXX motif that binds AP-3 and controls endosomal distribution and restriction breadth, with the protein adopting multiple membrane topologies.

    Evidence Site-directed mutagenesis, deconvolution microscopy, AP-3 Co-IP and knockdown, and SCAM topology mapping

    PMID:25527505

    Open questions at the time
    • Functional consequence of multiple co-existing topologies unknown
    • How distribution shifts translate into altered restriction mechanistically unclear
  11. 2013 High

    Identified S-palmitoylation of conserved cysteines as essential for IFITM1 antiviral activity and protein stability, establishing a post-translational switch controlling function.

    Evidence Palmitoylation assays, cysteine mutagenesis, proteasome inhibition, and influenza A and HCV infection assays

    PMID:23804635 PMID:26354436

    Open questions at the time
    • Palmitoyltransferases acting on IFITM1 not identified in these studies
    • Why the N-terminal tyrosine is dispensable for IFITM1 but not IFITM2/3 not mechanistically explained
  12. 2013 Medium

    Mapped IFITM1's antiviral specificity by negative results, showing it fails to restrict RVFV, HPV16, HCMV, and Ad5 and even modestly enhances HPV16, refining which viruses it acts upon and where its compartments differ from IFITM2/3.

    Evidence Overexpression of individual IFITMs with viral restriction assays and vesicle compartment imaging across multiple cell types

    PMID:23720721 PMID:24827144

    Open questions at the time
    • Mechanism of HPV16 enhancement not defined
    • Compartment differences described but not functionally tested
  13. 2014 Medium

    Demonstrated viral evolutionary escape from IFITM1 via vpu and env mutations promoting cell-to-cell spread, illuminating how restriction is countered.

    Evidence Serial passage of HIV-1 in IFITM1-expressing SupT1 cells with genome sequencing and cell-to-cell transmission assays

    PMID:24725927

    Open questions at the time
    • Direct molecular interaction between IFITM1 and viral proteins not shown
    • Generalizability beyond passaged strains uncertain
  14. 2015 Medium

    Showed that the C-terminal sorting signal restrains IFITM1 anti-HIV activity by keeping it off the plasma membrane, explaining why human IFITM1 normally fails to block HIV entry.

    Evidence C-terminal deletion mutagenesis, subcellular localization imaging, HIV-1 entry assays, and human vs. mouse comparison

    PMID:25738301

    Open questions at the time
    • Effect modest (3-fold) and confined to a deletion mutant
    • Physiological relevance of relocated IFITM1 unclear
  15. 2017 High

    Resolved how IFN coordinately induces the IFITM cluster, showing STAT1 binds a distal enhancer that loops to the IFITM genes and is required for antiviral resistance in vivo.

    Evidence Luciferase reporter, ChIP, EMSA, 3C chromosome conformation capture, and CRISPR in vivo enhancer truncation

    PMID:28511927

    Open questions at the time
    • Relative contribution of each IFITM gene to the in vivo phenotype not separated
    • Looping architecture not resolved at base-pair detail
  16. 2017 Medium

    Revealed epigenetic and developmental functions, showing IFITM1 silences HERVs via H3K9me3 and contributes to IFN-γ/TNF-α antiproliferative control of keratinocytes, broadening its non-viral repertoire.

    Evidence CRISPR/Cas9 knockout in hESCs with HERV expression and H3K9me3 ChIP; siRNA knockdown with proliferation and RARRES1 readouts in keratinocytes

    PMID:27920775 PMID:28781951

    Open questions at the time
    • How a transmembrane protein influences chromatin marks at HERV loci is mechanistically unexplained
    • Direct versus indirect epigenetic effects not distinguished
  17. 2019 Medium

    Diversified IFITM1's expression control, identifying MUC1-STAT1, NF-κB/IRF1 enhancer engagement, BAF200/PBAF for basal expression, and G3BP-dependent protein accumulation as distinct regulatory inputs.

    Evidence siRNA/inhibitor studies, ChIP-seq and luciferase enhancer assays, yeast two-hybrid and Co-IP, and 3'-UTR interaction assays across cell models

    PMID:30655323 PMID:31075894 PMID:31172368 PMID:31910882

    Open questions at the time
    • G3BP regulation rests on incompletely characterized methods (Low confidence)
    • Hierarchy among these regulatory inputs in a single cell type unresolved
  18. 2019 Medium

    Connected IFITM1 to MHC class I immune surveillance, showing IFITM1/3 are needed for IFN-γ-stimulated HLA-B and ISG15 synthesis and associate with ISG15 and HLA-B.

    Evidence CRISPR double KO, pulse SILAC, SWATH-IP mass spectrometry, proximity ligation, and siRNA in cervical cancer cells

    PMID:30951861

    Open questions at the time
    • Whether interactions are direct not established by PLA alone
    • Step in HLA-B production affected not yet defined here
  19. 2022 Medium

    Localized IFITM1's role in HLA-B production to translation, showing it interacts with SRSF1 and HLA-B mRNA and that its loss reduces HLA-B protein without lowering mRNA.

    Evidence SBP-tagged pulldown/MS, protein- and RNA-PLA, and ribosome profiling by sucrose gradient sedimentation

    PMID:36008984

    Open questions at the time
    • Mechanism by which a membrane protein engages translation machinery unclear
    • Direct RNA binding versus complex-mediated association not separated
  20. 2023 High

    Established IFITM1 as a metastasis suppressor in brain colonization through dual immune surveillance: C3-mediated microglial activation and increased MHC-I to enable CD8+ T cell killing.

    Evidence In vivo genome-wide CRISPR screen with co-culture, MHC-I surface, C3 secretion, CD8+ killing, and PD-1 blockade mouse assays

    PMID:36799040

    Open questions at the time
    • How IFITM1 drives C3 secretion mechanistically unknown
    • Tissue specificity of this protective role versus pro-tumor roles unresolved
  21. 2023 Medium

    Reframed IFITM1 as a cholesterol-trafficking factor that a non-enveloped virus hijacks, showing it moves cholesterol from late endosomes to the Golgi and assembles with ACBD3, PI4KB, and OSBP at Aichi virus replication sites.

    Evidence siRNA knockdown, overexpression, Co-IP with ACBD3/PI4KB/OSBP, cholesterol imaging, and pharmacological transport inhibition

    PMID:37252940

    Open questions at the time
    • Whether cholesterol transport is the native cellular function or a co-opted one unclear
    • Direct versus indirect interaction with Golgi proteins not parsed
  22. 2023 Medium

    Extended IFITM1's context-dependent roles to cancer invasion and induction pathways, linking it to invasive lung adenocarcinoma via PLK1-FoxM1-STING-TBK1-IRF3 and to suppression of trophoblast invasion.

    Evidence ChIP, kinase assays, and mutagenesis in LUAD; invasion assays, lentiviral transduction, poly(I:C) mouse, and placenta immunostaining for trophoblasts

    PMID:37434700 PMID:37968723

    Open questions at the time
    • Opposing pro- and anti-invasive effects across tissues not mechanistically reconciled
    • Direct effectors of invasion control not pinned down
  23. 2025 Medium

    Identified the palmitoylation eraser/writer network controlling IFITM1, showing ABHD16A depalmitoylates and inhibits IFITM1 antiviral activity while ABHD17A enhances it indirectly by suppressing ABHD16A.

    Evidence Co-IP, acyl-PEG exchange palmitoylation assays, ABHD16A/ABHD17A perturbation, and CRISPR KO with anti-HBV replication readouts

    PMID:40434075 PMID:40723864

    Open questions at the time
    • Identity of the palmitoyltransferase writer not established here
    • Whether ABHD17A acts solely through ABHD16A in all contexts unclear
  24. 2025 Medium

    Broadened IFITM1's tissue functions to vascular and epithelial proliferation, implicating c-Src/MAPK/GATA2/E2F2 signaling in atherosclerosis and OVOL1 inhibition in corneal stem cell expansion.

    Evidence RNA-seq, pathway Western blots, proliferation/migration assays, ApoE-/- plaque model, and scRNA-seq with AAV in vivo knockdown

    PMID:40372397 PMID:40466954

    Open questions at the time
    • Direct molecular targets linking IFITM1 to these pathways not defined
    • Generalizability across tissues unproven

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how a single small transmembrane protein integrates such divergent activities—viral entry restriction, cholesterol trafficking, translational control of HLA-B, chromatin/HERV regulation, and tissue-specific proliferation—and whether these reflect distinct topologies, palmitoylation states, or partner complexes.
  • No unified structural model linking topology and palmitoylation to specific functions
  • Direct biochemical activity (channel, transporter, scaffold) not definitively assigned
  • Tissue determinants of pro- versus anti-tumor behavior unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 2 GO:0140313 molecular sequestering activity 2 GO:0003723 RNA binding 1 GO:0008289 lipid binding 1
Localization
GO:0005886 plasma membrane 3 GO:0005768 endosome 2 GO:0005794 Golgi apparatus 1 GO:0005829 cytosol 1
Pathway
R-HSA-1643685 Disease 3 R-HSA-168256 Immune System 3 R-HSA-162582 Signal Transduction 2 R-HSA-74160 Gene expression (Transcription) 1
Partners
ABHD16AABHD17AAP-3CAV1CD81HLA-BOCLNSRSF1
Complex memberships
hepatocyte tight junction

Evidence

Reading pass · 38 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1993 The IFITM1 protein (encoded by the interferon-inducible 9-27 gene) binds RNA in vitro and inhibits HIV-1 expression by blocking Rev-dependent post-transcriptional steps of viral gene expression when transfected into human cells. cDNA library screen for RRE-binding proteins, in vitro RNA-binding assay, transfection with HIV-1 expression assay Science Medium 7680491
1996 IFITM1 (9-27 protein) has intrinsic antiviral activity against vesicular stomatitis virus (VSV) but not influenza virus; its intracellular distribution resembles that of cytoskeleton-associated proteins. Constitutive expression of 9-27 cDNA in mouse cells, indirect immunofluorescence, single-cell virus resistance assay Journal of interferon & cytokine research Medium 8727077
1998 The rat ortholog of IFITM1 (rat8/9-27 homolog) is required for dome formation in mammary epithelial cells; antisense suppression abolishes dome formation, while forced expression in non-dome-forming cells induces morphological changes suggesting tightened lateral cell connections; the gene is expressed in epithelial tubular structures. Subtractive cDNA library, antisense treatment, forced overexpression, in situ hybridization PNAS Medium 9448288
2005 Mouse IFITM1 mediates repulsion of primordial germ cells (PGCs) from the posterior mesoderm into the endoderm via a repulsive mechanism; this activity requires the N-terminal extracellular domain of IFITM1, which cannot be substituted by another IFITM family member's N-terminal domain. Loss-of-function experiments in mouse embryos, domain-swap/chimeric protein analysis, PGC migration tracking Developmental cell High 16326387
2006 IFITM1 is required downstream of STAT1 for IFN-γ-mediated antiproliferative effects; IFITM1 overexpression inhibits ERK activity, enhances p53 transcriptional activity, and stabilizes p53 by preventing phosphorylation at Thr55; knockdown of IFITM1 blocks IFN-γ antiproliferative activity and confers tumorigenicity to non-malignant hepatocytes. Overexpression and siRNA knockdown of IFITM1, ERK activity assay, p53 transcriptional reporter assay, phosphorylation analysis, nude mouse tumorigenicity assay Oncogene High 16847454
2009 IFITM1 localizes to caveolae of the plasma membrane and physically interacts with caveolin-1 (CAV-1) through its hydrophobic transmembrane domains; this interaction enhances CAV-1's inhibitory effect on ERK phosphorylation, without IFITM1 directly activating ERK. Immunofluorescence, co-immunoprecipitation, deletion mutagenesis, ERK phosphorylation assay, siRNA knockdown of CAV-1 Acta biochimica et biophysica Sinica Medium 19499152
2010 CD147 activation by cyclophilin A induces IFITM1 expression via ERK, PI3K, and NF-κB signaling pathways (but not p38, JNK, or PKC); cross-linking of IFITM1 with a monoclonal antibody induces expression of proinflammatory mediators IL-8 and MMP-9 in THP-1 macrophages. Pathway inhibitors (ERK, PI3K, NF-κB, p38, JNK, PKC), RT-PCR, Western blot, antibody cross-linking of IFITM1 Mediators of inflammation Medium 20847954
2011 Exogenous expression of IFITM1 inhibits HCV replication in immortalized human hepatocytes (IHH) and Huh7 cells, and knockdown enhances HCV replication; IFITM1 overexpression does not block HCV pseudotype entry, suggesting action at a post-entry step. Overexpression and siRNA knockdown in IHH and Huh7 cells, HCV replication assay, HCV pseudotype entry assay Journal of virology Medium 21976647
2012 IFITM1 is a hepatocyte tight junction protein that interacts with HCV co-receptors CD81 and occludin to disrupt viral entry; IFITM1 accumulates at hepatic tight junctions during IFN therapy in HCV-infected patient liver. Co-immunoprecipitation (IFITM1 with CD81 and occludin), immunofluorescence/confocal microscopy of tight junction localization, patient liver biopsy immunostaining, functional HCV entry assays Hepatology High 22996292
2013 IFITM1 restricts virus entry and its intracellular distribution is governed by a C-terminal non-canonical dibasic sorting signal (KRXX); mutating the two basic residues (KR/AA) increases restriction of jaagsiekte sheep retrovirus (JSRV) and amphotropic MLV by altering distribution toward CD63+ multivesicular bodies and away from LAMP1+ lysosomes; IFITM1 binds adaptor protein complex 3 (AP-3), and this association is lost when the dibasic motif is mutated; IFITM1 adopts more than one membrane topology co-existing in cellular membranes. Site-directed mutagenesis of KRXX motif, deconvolution microscopy, co-immunoprecipitation with AP-3, AP-3 knockdown, substituted cysteine accessibility method (SCAM) for topology Journal of Biological Chemistry High 25527505
2013 S-palmitoylation of IFITM1 on conserved and non-conserved cysteines is required for anti-influenza A virus activity; palmitoylation also prevents proteasomal degradation of IFITM1; palmitoylation of the nonconserved C-terminal cysteine supports an intramembrane topology. Palmitoylation assays, site-directed cysteine mutagenesis, proteasome inhibitor treatment, influenza A virus infection assay Journal of virology High 23804635
2013 S-palmitoylation of all three IFITM proteins (including IFITM1) is essential for anti-HCV activity; the conserved tyrosine residue in the N-terminal domain of IFITM1 is dispensable for anti-HCV activity (in contrast to IFITM2/3 where it regulates localization); IFITM2/3 localize to late and early endosomes and lysosomes in hepatocytes, while IFITM1 co-localizes with CD81. S-palmitoylation assays, site-directed mutagenesis of cysteines and tyrosine residues, HCV entry and replication assays, subcellular co-localization immunofluorescence Journal of Biological Chemistry High 26354436
2013 IFITM-1 does not restrict Rift Valley fever virus (RVFV) infection, while IFITM-2 and IFITM-3 do; IFITM-1 occupies vesicular compartments distinct from those occupied by IFITM-2 and -3. Overexpression of individual IFITMs, viral infection assays with RVFV, vesicle compartment imaging Journal of virology Medium 23720721
2014 HIV-1 can mutate to evade IFITM1 restriction; mutations in vpu (Vpu34, introducing a premature stop) and env (EnvG367E at the CD4-binding site of gp120) together enable HIV-1 replication in IFITM1-expressing cells by promoting cell-to-cell virus transmission rather than overcoming IFITM1-mediated downregulation of p24 expression. Serial passage of HIV-1 in IFITM1-expressing SupT1 cells, full genome sequencing, mutant virus functional assays, cell-to-cell transmission assay Virology Medium 24725927
2014 IFITM1 does not inhibit infection by HPV16, human cytomegalovirus (HCMV), or adenovirus type 5; IFITM1 and IFITM3 modestly enhanced HPV16 infection in multiple cell types including primary keratinocytes. Overexpression in multiple cell types including primary keratinocytes, viral infection assays for HPV16, HCMV, and Ad5 PLoS One Medium 24827144
2015 The C-terminal 9 amino acids of IFITM1 contain a sorting signal that suppresses anti-HIV-1 activity; deletion of residues 117–125 (Δ117-125) relocates IFITM1 predominantly to the plasma membrane where HIV-1 entry occurs and enables 3-fold inhibition of HIV-1 entry; wild-type human IFITM1 (which has a longer C-terminus compared to mouse IFITM1) does not inhibit HIV-1 entry. C-terminal deletion mutagenesis, subcellular localization imaging, HIV-1 entry assay, comparison of human vs. mouse IFITM1 PLoS One Medium 25738301
2015 IFITM1 loss of function in AI-resistant MCF-7:5C cells markedly increases p21 transcription, expression, and nuclear localization mediated by JAK/STAT activation; IFITM1 overexpression in wild-type MCF-7 cells promotes estrogen-independent growth. Lentivirus shRNA knockdown, overexpression, orthotopic and MIND mouse models, p21 reporter assays, JAK/STAT inhibition Cancer letters Medium 28411130
2016 IFITM1 promotes CRC cell migration/invasion through a mechanism involving CAV-1 as a downstream target; knockdown of CAV-1 abrogates IFITM1-siRNA-mediated inhibition of cell invasion, placing CAV-1 downstream of IFITM1 in a pro-invasive pathway. Overexpression and siRNA knockdown of IFITM1, siRNA knockdown of CAV-1, migration/invasion assays, epistasis rescue experiment Oncotarget Medium 27852071
2016 IFITM1 overexpression in SUM149 IBC cells promotes aggressiveness in a STAT2-dependent manner; STAT2 knockdown abolishes IFITM1 expression and IFITM1 promoter activity; STAT2-mediated IFITM1 activation is dependent on the chromatin remodeler BRG1. siRNA/shRNA knockdown of IFITM1, STAT1/2, and BRG1; luciferase promoter assays; migration, invasion, and colony formation assays Breast cancer research Medium 26897526
2017 An IFN-responsive enhancer located 35 kb upstream of IFITM3 coordinately upregulates IFN-induced expression of IFITM1, IFITM2, and IFITM3 genes; STAT1 binds this enhancer upon IFN treatment; chromatin looping brings the IFITM gene cluster into physical contact with this distal enhancer; in vivo truncation of the enhancer impairs IFN-induced resistance to influenza A virus. Luciferase reporter assay, CRISPR-Cas9 genome editing (in vivo enhancer truncation), ChIP assay, EMSA, 3C (chromosome conformation capture) Biochimica et biophysica acta. Gene regulatory mechanisms High 28511927
2017 HPV infection downregulates IFITM1 expression; knockdown of IFITM1 in uninfected keratinocytes confirms its role in IFN-γ/TNF-α-mediated antiproliferative effects and in regulating RARRES1 expression. siRNA knockdown of IFITM1, cell growth/proliferation assays, gene expression analysis, S-phase arrest analysis Frontiers in immunology Medium 27920775
2017 IFITM1 suppresses expression of human endogenous retroviruses (HERVs) in human embryonic stem cells (hESCs) by regulating epigenetic modifications; IFITM1 knockout (CRISPR/Cas9) increases HERV expression and reduces trimethylation of H3K9 at HERV loci. CRISPR/Cas9 knockout of IFITM1 in hESCs, HERV expression analysis, H3K9me3 ChIP at HERV loci FEBS open bio Medium 28781951
2019 G3BP1 and G3BP2 RNA-binding proteins are essential for the accumulation of IFITM1 protein and regulate IFITM1 expression through both the MEK pathway and interaction with the 3'-UTR of IFITM1 transcripts. G3BP knockdown, MEK pathway inhibition, 3'-UTR interaction assays, Western blot of IFITM protein levels Molecular and cellular biochemistry Low 31172368
2019 IFITM1 and IFITM3 double knockout in cervical cancer cells attenuates IFNγ-stimulated synthesis of IRF1, HLA-B, and ISG15; SBP-tagged IFITM1 co-associates with ISG15 and HLA-B by SWATH-IP mass spectrometry; HLA-B interacts with IFITM1/3 by proximity ligation assay; ISG15ylation is attenuated in IFITM1/IFITM3 double-null cells; IFITM1-targeted siRNA attenuates an IFN-regulated protein subpopulation including MHC Class I molecules. CRISPR-Cas9 double KO, pulse SILAC, SWATH-IP mass spectrometry, proximity ligation assay, siRNA knockdown Cellular signalling Medium 30951861
2019 MUC1 interacts with STAT1 via JAK/STAT signaling to drive IFITM1 transcription; knockdown of MUC1 by siRNA or pharmacological inhibitors abrogates IFITM1 mRNA and protein expression; in vivo, estrogen and ruxolitinib reduce MUC1, P-STAT1, and IFITM1 expression. siRNA knockdown of MUC1, pharmacological inhibitors, Western blot, in vivo mouse model with ruxolitinib treatment Molecular cancer research Medium 30655323
2019 HBV core protein (HBc) inhibits IFNα-induced IFITM1 expression by interacting with BAF200 (a component of the PBAF chromatin remodeling complex); basal IFITM1 expression depends on BAF200, not the JAK-STAT1 pathway; HBc-BAF200 interaction disrupts PBAF complex stability and suppresses IFITM1 transcription. Yeast two-hybrid, co-immunoprecipitation (HBc-BAF200 interaction), Western blot, HBV replication assay, co-transfection rescue experiments Viruses Medium 31075894
2019 NF-κB and IRF1 transcription factors bind an enhancer region (R2, 2 kb upstream) of the IFITM1 gene to mediate LPS-stimulated IFITM1 expression and hMSC migration; LPS treatment increases enhancer RNA expression at R2 and H3K27ac enrichment at R2; knockdown of IFITM1 impairs LPS-stimulated cell migration. ChIP sequencing, ChIP-PCR, luciferase reporter assay, qRT-PCR for enhancer RNAs, RNAi (NF-κB and IRF1), wound healing assay Stem cell research & therapy Medium 31910882
2021 IFITM1 expression determined by APC/Wnt signaling controls extracellular vesicle (EV) uptake in colorectal cancer; APC mutation induces IFITM1 expression; IFITM1high CRC cells show markedly reduced uptake of fibroblast EVs; inactivation of IFITM1 enhances EV uptake. Mouse and patient-derived organoids, APC mutation models, IFITM1 knockout/knockdown, EV uptake assays Cellular and molecular life sciences Medium 34609520
2021 NF-κB is an important downstream target of IFITM1 in TNBC; siRNA/CRISPR KO of IFITM1 inhibits proliferation, colony formation, and wound healing in vitro and reduces tumor growth/invasion in vivo; RNA-seq of IFITM1 KO cells reveals downregulation of genes involved in proliferation, migration, and invasion. siRNA and CRISPR/Cas9 knockout, RNA-seq, orthotopic and MIND mouse models, NF-κB siRNA rescue experiments Cancer letters Medium 34022283
2022 IFITM1 associates with the splicing factor SRSF1 (predominantly in the cytosol); IFITM1/3 interact with HLA-B mRNA in response to IFNγ; IFITM1/3 double KO cells show a reduction in the 80S ribosomal fraction; loss of IFITM1/3 reduces HLA-B protein synthesis without affecting HLA-B mRNA levels, placing IFITM1 function at the translational rather than transcriptional level for HLA-B. SBP-tagged IFITM1 pulldown/MS, proximity ligation assay (protein-protein and RNA-protein), ribosome profiling by sucrose gradient sedimentation, RT-qPCR, RNA-seq Biomolecules Medium 36008984
2023 IFITM1 high expression in incipient brain metastatic lung cancer cells mediates immune surveillance by: secreting complement component C3 to activate microglia and by increasing MHC class I surface expression to enhance CD8+ T cell cytolytic activity; loss of IFITM1 promotes brain colonization by escaping both innate (microglia phagocytosis) and adaptive (CD8+ T cell killing) immune responses. In vivo genome-wide CRISPR-Cas9 screen, IFITM1 overexpression/knockdown, co-culture assays, MHC-I surface expression assays, C3 secretion measurement, CD8+ T cell killing assay, PD-1 blockade mouse model EMBO journal High 36799040
2023 IFITM1 facilitates cholesterol transport from late endosomes to the Golgi, which is exploited by Aichi virus (a non-enveloped RNA virus) to form cholesterol-rich replication sites; IFITM1 localizes to viral RNA replication sites; IFITM1 interacts with viral proteins and host Golgi proteins ACBD3, PI4KB, and OSBP at replication sites; IFITM1 knockdown significantly reduces AiV RNA replication. siRNA knockdown, overexpression, co-immunoprecipitation (IFITM1 with ACBD3, PI4KB, OSBP), fluorescence imaging of cholesterol distribution, pharmacological inhibition of ER-Golgi cholesterol transport PLoS pathogens Medium 37252940
2023 IFN-β-induced IFITM1 upregulation impairs extravillous cytotrophoblast (EVCT) invasion; transduction of IFITM1 into trophoblast cells directly reduces invasive ability; IFITM1 is upregulated in CMV- and bacterially infected human placentas. In vitro/ex vivo EVCT invasion assays, IFITM1 transduction (lentiviral), in vivo poly(I:C) mouse model, human pathological placenta immunostaining iScience Medium 37434700
2023 IFITM1 is upregulated in invasive lung adenocarcinoma (LUAD) with phosphomimetic FoxM1 (phosphorylated at Ser25 by PLK1) through activation of the STING-TBK1-IRF3 signaling pathway. Immunoprecipitation, kinase assay, site-directed mutagenesis, chromatin immunoprecipitation, microarray analysis, LC-MS/MS Journal of experimental & clinical cancer research Medium 37968723
2025 ABHD17A physically interacts with IFITM1 and paradoxically increases its S-palmitoylation level (and thereby antiviral activity) not by directly palmitoylating it, but by downregulating the depalmitoylase ABHD16A; ABHD16A catalyzes depalmitoylation of IFITM1 and negatively regulates its antiviral activity, and ABHD17A counteracts this by suppressing ABHD16A. Co-immunoprecipitation, acyl-PEG exchange gel-shift palmitoylation assay, ABHD16A knockdown/overexpression, antiviral activity assays Biomolecules Medium 40723864
2025 ABHD16A catalyzes depalmitoylation of IFITM1 in HepG2.215 cells and negatively regulates its anti-HBV activity; CRISPR/Cas9 knockout of ABHD16A enhances IFITM1-mediated restriction of HBV replication; the anti-HBV activity of IFITM1 depends on palmitoylation modification. Co-immunoprecipitation, acyl-PEGyl exchange gel-shift assay (APEGS), CRISPR/Cas9 knockout of IFITM1 and ABHD16A, HBV replication assay Microbiology spectrum Medium 40434075
2025 IFITM1 promotes VSMC proliferation, migration, and macrophage-like transdifferentiation via the c-Src/MAPK/GATA2/E2F2 signaling pathway; overexpression of IFITM1 upregulates p-Src, p-p38 MAPK, p-GATA2, and E2F2 levels; in vivo overexpression accelerates atherosclerotic plaque formation in ApoE-/- mice. RNA sequencing, Western blot (pathway intermediates), cell viability/flow cytometry/wound healing/transwell assays, ApoE-/- mouse model, IFITM1 overexpression Biochemical pharmacology Medium 40466954
2025 IFITM1 promotes limbal epithelial stem/early transient amplifying (eTA) cell expansion after corneal wounding partly through inhibition of OVOL1, a negative regulator of epithelial cell proliferation; in vivo AAV-mediated knockdown of IFITM1 significantly attenuates stem/eTA cell expansion and activation after corneal injury. Single-cell RNA sequencing, AAV-mediated in vivo IFITM1 knockdown, human limbal epithelial cell proliferation assays, OVOL1 pathway analysis FASEB journal Medium 40372397

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2005 IFITM/Mil/fragilis family proteins IFITM1 and IFITM3 play distinct roles in mouse primordial germ cell homing and repulsion. Developmental cell 163 16326387
2013 The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. Journal of virology 159 23658454
2015 The Interferon-induced Transmembrane Proteins, IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C Virus Entry. The Journal of biological chemistry 148 26354436
2012 IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology (Baltimore, Md.) 133 22996292
2011 ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. Journal of virology 129 21976647
2013 IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. Journal of virology 110 23720721
2006 IFITM1 plays an essential role in the antiproliferative action of interferon-gamma. Oncogene 108 16847454
2012 Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. Journal of virology 82 22787204
2013 Palmitoylation on conserved and nonconserved cysteines of murine IFITM1 regulates its stability and anti-influenza A virus activity. Journal of virology 73 23804635
2015 IFITM1 promotes the metastasis of human colorectal cancer via CAV-1. Cancer letters 71 26259513
2010 Knockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells. Journal of neuro-oncology 68 20838853
2016 Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner. Breast cancer research : BCR 67 26897526
2014 The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus. PloS one 66 24827144
2005 The interferon-inducible 9-27 gene modulates the susceptibility to natural killer cells and the invasiveness of gastric cancer cells. Cancer letters 61 15808405
2017 IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21. Cancer letters 50 28411130
2012 Overexpression of IFITM1 has clinicopathologic effects on gastric cancer and is regulated by an epigenetic mechanism. The American journal of pathology 48 22609115
1993 Inhibition of Rev-mediated HIV-1 expression by an RNA binding protein encoded by the interferon-inducible 9-27 gene. Science (New York, N.Y.) 48 7680491
1996 Partial inhibition of vesicular stomatitis virus by the interferon-induced human 9-27 protein. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 43 8727077
1991 Differential response of the human 6-16 and 9-27 genes to alpha and gamma interferons. Nucleic acids research 43 1901407
2014 A sorting signal suppresses IFITM1 restriction of viral entry. The Journal of biological chemistry 39 25527505
2023 Invasive FoxM1 phosphorylated by PLK1 induces the polarization of tumor-associated macrophages to promote immune escape and metastasis, amplified by IFITM1. Journal of experimental & clinical cancer research : CR 38 37968723
2019 Bat IFITM3 restriction depends on S-palmitoylation and a polymorphic site within the CD225 domain. Life science alliance 37 31826928
2016 Interferon-induced transmembrane protein 1 (IFITM1) is required for the progression of colorectal cancer. Oncotarget 37 27852071
2019 Inhibiting of Proliferation, Migration, and Invasion in Lung Cancer Induced by Silencing Interferon-Induced Transmembrane Protein 1 (IFITM1). BioMed research international 36 31205947
2014 HIV-1 mutates to evade IFITM1 restriction. Virology 36 24725927
2019 Porcine IFITM1 is a host restriction factor that inhibits pseudorabies virus infection. International journal of biological macromolecules 35 31743714
2005 Expression of IFITM1 in chronic myeloid leukemia patients. Leukemia research 35 15661263
2020 Deciphering the Roles of IFITM1 in Tumors. Molecular diagnosis & therapy 34 32394410
2019 The effects of IFITM1 and IFITM3 gene deletion on IFNγ stimulated protein synthesis. Cellular signalling 33 30951861
2015 The C-terminal sequence of IFITM1 regulates its anti-HIV-1 activity. PloS one 33 25738301
2014 Porcine reproductive and respiratory syndrome virus counteracts the porcine intrinsic virus restriction factors-IFITM1 and Tetherin in MARC-145 cells. Virus research 33 25102331
2018 Combination of IFITM1 knockdown and radiotherapy inhibits the growth of oral cancer. Cancer science 32 29770536
2010 Activation of CD147 with cyclophilin a induces the expression of IFITM1 through ERK and PI3K in THP-1 cells. Mediators of inflammation 30 20847954
2008 Selection of a novel drug-response predictor in esophageal cancer: a novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response. International journal of oncology 29 18202764
2018 IFITM1 Outperforms CD10 in Differentiating Low-grade Endometrial Stromal Sarcomas From Smooth Muscle Neoplasms of the Uterus. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 28 28700435
2017 miRNA-36 inhibits KSHV, EBV, HSV-2 infection of cells via stifling expression of interferon induced transmembrane protein 1 (IFITM1). Scientific reports 28 29269892
2021 Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression. Cancer letters 27 34022283
2019 Interaction Between MUC1 and STAT1 Drives IFITM1 Overexpression in Aromatase Inhibitor-Resistant Breast Cancer Cells and Mediates Estrogen-Induced Apoptosis. Molecular cancer research : MCR 26 30655323
2016 Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNγ- and TNFα-Mediated Antiproliferative Effects and Necroptosis. Frontiers in immunology 25 27920775
2022 CircVPS13C promotes pituitary adenoma growth by decreasing the stability of IFITM1 mRNA via interacting with RRBP1. Oncogene 24 35091683
2021 Long Non-coding RNA LINC00847 Induced by E2F1 Accelerates Non-small Cell Lung Cancer Progression Through Targeting miR-147a/IFITM1 Axis. Frontiers in medicine 24 33968966
2014 Aberrant DNA methylation in the IFITM1 promoter enhances the metastatic phenotype in an intraperitoneal xenograft model of human ovarian cancer. Oncology reports 24 24676393
2013 Targeted development of specific biomarkers of endometrial stromal cell differentiation using bioinformatics: the IFITM1 model. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 24 24072182
2009 Binding of IFITM1 enhances the inhibiting effect of caveolin-1 on ERK activation. Acta biochimica et biophysica Sinica 24 19499152
2012 Interferons induce the expression of IFITM1 and IFITM3 and suppress the proliferation of rat neonatal cardiomyocytes. Journal of cellular biochemistry 23 22021094
1998 The rat gene homologous to the human gene 9-27 is involved in the development of the mammary gland. Proceedings of the National Academy of Sciences of the United States of America 23 9448288
2019 G3BP1 and G3BP2 regulate translation of interferon-stimulated genes: IFITM1, IFITM2 and IFITM3 in the cancer cell line MCF7. Molecular and cellular biochemistry 22 31172368
2013 Evidence for Paralichthys olivaceus IFITM1 antiviral effect by impeding viral entry into target cells. Fish & shellfish immunology 21 23850425
2012 IFITM1 increases osteogenesis through Runx2 in human alveolar-derived bone marrow stromal cells. Bone 21 22634173
2021 CD225 Proteins: A Family Portrait of Fusion Regulators. Trends in genetics : TIG 20 33518406
2021 IFITM1 expression determines extracellular vesicle uptake in colorectal cancer. Cellular and molecular life sciences : CMLS 19 34609520
2018 Upregulation of PITX2 Promotes Letrozole Resistance Via Transcriptional Activation of IFITM1 Signaling in Breast Cancer Cells. Cancer research and treatment 19 30025446
2023 Immune surveillance of brain metastatic cancer cells is mediated by IFITM1. The EMBO journal 18 36799040
2020 Interferon-Induced Transmembrane Protein 1 (IFITM1) Promotes Distant Metastasis of Small Cell Lung Cancer. International journal of molecular sciences 18 32668617
2019 Human Hepatitis B Virus Core Protein Inhibits IFNα-Induced IFITM1 Expression by Interacting with BAF200. Viruses 18 31075894
2017 Down-regulation of IFITM1 and its growth inhibitory role in cervical squamous cell carcinoma. Cancer cell international 18 29051711
2024 Identification of core immune-related genes CTSK, C3, and IFITM1 for diagnosing Helicobacter pylori infection-associated gastric cancer through transcriptomic analysis. International journal of biological macromolecules 17 39667460
2021 Transgenic Chicks Expressing Interferon-Inducible Transmembrane Protein 1 (IFITM1) Restrict Highly Pathogenic H5N1 Influenza Viruses. International journal of molecular sciences 17 34445163
2017 Coordinated regulation of IFITM1, 2 and 3 genes by an IFN-responsive enhancer through long-range chromatin interactions. Biochimica et biophysica acta. Gene regulatory mechanisms 17 28511927
2023 IFITM1 inhibits trophoblast invasion and is induced in placentas associated with IFN-mediated pregnancy diseases. iScience 15 37434700
2021 IFITM1, CD10, SMA, and h-caldesmon as a helpful combination in differential diagnosis between endometrial stromal tumor and cellular leiomyoma. BMC cancer 14 34556086
2020 IFITM1 is a Novel, Highly Sensitive Marker for Endometriotic Stromal Cells in Ovarian and Extragenital Endometriosis. Reproductive sciences (Thousand Oaks, Calif.) 14 32436195
2018 IFITM1 expression is crucial to gammaherpesvirus infection, in vivo. Scientific reports 14 30237526
2017 Identification of IFITM1 and IFITM3 in Goose: Gene Structure, Expression Patterns, and Immune Reponses against Tembusu Virus Infection. BioMed research international 14 28386554
2022 Co-expression of DDR2 and IFITM1 promotes breast cancer cell proliferation, migration and invasion and inhibits apoptosis. Journal of cancer research and clinical oncology 13 35761108
2017 IFITM1 suppresses expression of human endogenous retroviruses in human embryonic stem cells. FEBS open bio 13 28781951
2012 In vivo functional requirement of the mouse Ifitm1 gene for germ cell development, interferon mediated immune response and somitogenesis. PloS one 13 23115618
2022 Differential Leukocyte Expression of IFITM1 and IFITM3 in Patients with Severe Pandemic Influenza A(H1N1) and COVID-19. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 12 35708622
2020 Epigenetic regulation of IFITM1 expression in lipopolysaccharide-stimulated human mesenchymal stromal cells. Stem cell research & therapy 12 31910882
2017 IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis. JCI insight 12 28097226
2023 Oncostatin M Induces IFITM1 Expression to Inhibit Hepatitis B Virus Replication Via JAK-STAT Signaling. Cellular and molecular gastroenterology and hepatology 11 37879404
2022 Comparative transcriptome reveals the effect of IFITM1 on differential resistance to duck hepatitis A virus genotype 3 in Pekin ducks. Virus research 11 36130655
2021 The first association study of single-nucleotide polymorphisms (SNPs) of the IFITM1 gene with influenza H1N1 2009 pandemic virus infection. Molecular & cellular toxicology 11 33613683
2005 IFITM1-mediated cell repulsion controls the initial steps of germ cell migration in the mouse. Developmental cell 11 16326382
2016 IFITM1 Is Superior to CD10 as a Marker of Endometrial Stroma in the Evaluation of Myometrial Invasion by Endometrioid Adenocarcinoma. American journal of clinical pathology 10 27124937
2016 KLF5 is involved in regulation of IFITM1, 2, and 3 genes during H5N1 virus infection in A549 cells. Cellular and molecular biology (Noisy-le-Grand, France) 10 28040064
2013 Brahma‑related gene 1-associated expression of 9-27 and IFI-27 is involved in acquired cisplatin resistance of gastric cancer cells. Molecular medicine reports 10 23836109
2013 Identification of the polymorphisms in IFITM1 gene and their association in a Korean population with ulcerative colitis. Immunology letters 9 24120510
2024 SNARE mimicry by the CD225 domain of IFITM3 enables regulation of homotypic late endosome fusion. The EMBO journal 8 39653855
2023 Association of IFITM1 Promoter Methylation with Severity of SARS-CoV-2 Infection. Clinical laboratory 7 37057950
2022 Interaction of SERINC5 and IFITM1/2/3 regulates the autophagy-apoptosis-immune network under CSFV infection. Virulence 7 36205528
2019 IFITM1 is a Novel, Highly Sensitive Marker for Endometriotic Stromal Cells in Ovarian and Extragenital Endometriosis. Reproductive sciences (Thousand Oaks, Calif.) 7 30791812
2019 Comparative analysis of the chicken IFITM locus by targeted genome sequencing reveals evolution of the locus and positive selection in IFITM1 and IFITM3. BMC genomics 7 30952207
2025 IFITM1 promotes proliferation, migration and macrophage-like transdifferentiation of vascular smooth muscle cells via c-Src/MAPK/GATA2/E2F2 pathway in atherosclerosis. Biochemical pharmacology 6 40466954
2025 The Unconventional Role of ABHD17A in Increasing the S-Palmitoylation and Antiviral Activity of IFITM1 by Downregulating ABHD16A. Biomolecules 6 40723864
2024 IFITM1 and IFITM2 inhibit the replication of senecavirus A by positive feedback with RIG-I signaling pathway. Veterinary microbiology 6 38484578
2019 NP and NS1 proteins of H5N1 virus significantly upregulated IFITM1, IFITM2, and IFITM3 in A549 cells. African health sciences 6 31148967
2015 Cloning and characterization of ifitm1 and ifitm3 expression during early zebrafish development. Zygote (Cambridge, England) 6 25613417
2024 Swine RNF5 positively regulates the antiviral activity of IFITM1 by mediating the degradation of ABHD16A. Journal of virology 5 39601593
2023 IFITM1 enhances nonenveloped viral RNA replication by facilitating cholesterol transport to the Golgi. PLoS pathogens 5 37252940
2022 Emergent Role of IFITM1/3 towards Splicing Factor (SRSF1) and Antigen-Presenting Molecule (HLA-B) in Cervical Cancer. Biomolecules 5 36008984
2022 MiR-504-3p Has Tumor-Suppressing Activity and Decreases IFITM1 Expression in Non-Small Cell Lung Cancer Cells. Genetic testing and molecular biomarkers 5 36027039
2018 Expression and Cellular Localization of IFITM1 in Normal and Injured Rat Spinal Cords. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 5 29300519
2017 WITHDRAWN: Silencing of Interferon-Induced Transmembrane Protein 1 (IFITM1) Inhibits Proliferation, Migration, and Invasion in Lung Cancer Cells. Oncology research 5 28109085
2025 Depalmitoylase ABHD16A negatively regulates the anti-hepatitis B virus activity of IFITM1. Microbiology spectrum 4 40434075
2024 The role and mechanism of IFITM1 in developing acquired cisplatin resistance in small cell lung cancer. Heliyon 4 38803858
2023 IFITM1 and IFITM3 Proteins Inhibit the Infectivity of Progeny HIV-1 without Disrupting Envelope Glycoprotein Clusters. Viruses 4 38140631
2025 IFITM1/OVOL1 Axis Is a Novel Regulator of the Expansion of the Limbal Epithelial Stem/Early Transient Amplifying Cell Population. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 3 40372397
2025 Carcinoma-associated fibroblast-derived exosomes lncRNA RORA-AS1 facilitates radiotherapy resistance of oral squamous cell carcinoma through the IFITM1/STAT axis. Biochimica et biophysica acta. Molecular cell research 3 40588135
2024 IFITM1 is a host restriction factor that inhibits porcine epidemic diarrhea virus infection. Journal of nanobiotechnology 2 39501328

Missed literature

Know a paper Affinage missed for IFITM1? Flag it for the maintainers and the community.

No submissions yet.